Beijing Kawin Technology Share-Holding Co., Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Beijing China (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2012
NCT01504334
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

KawinGreen Biotech Co., Ltd. | Kawin Technology Share-holding Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 8